Last edition
News about "Regeneron Pharmaceuticals"
FDA Approves Regeneron's Pasatru to Reduce New Bone Formation in FOP
Regeneron’s Pasatru has received FDA approval for adults with FOP, with Phase 3 OPTIMA data showing up to a 94 percent reduction in new heterotopic ossification lesions compared with placebo.
Regeneron Pharmaceuticals | 24/08/2026 | By News Bureau | 569
US FDA and EMA Accept Cemdisiran Regulatory Submissions for Generalised Myasthenia Gravis
The FDA and EMA have accepted regulatory submissions for cemdisiran to treat generalised Myasthenia Gravis (gMG). If approved, it could become the first siRNA therapy for gMG with convenient quarterly subcutaneous dosing.
Regeneron Pharmaceuticals | 25/06/2026 | By News Bureau | 156
US FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss
US Food and Drug Administration (FDA) approves Regeneron’s Otarmeni, the first AAV-based gene therapy, offering a potential treatment for severe-to-profound hearing loss.
Regeneron Pharmaceuticals | 27/04/2026 | By News Bureau | 168
Zuellig Pharma Signs Exclusive Distribution Deal with Regeneron to Launch Libtayo
Regeneron is a biotechnology company that invents, develops and commercialises life-transforming medicines for people with serious diseases.
Regeneron Pharmaceuticals | 28/08/2024 | By Aishwarya | 563
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy